BeiGene Ties Up With Novartis To Take PD-1 Global In $2.2bn+ Deal
Bets on China Data, Differentiation Strategy
Executive Summary
BeiGene has teamed up with Novartis to take its PD-1 antibody global after an earlier major deal with Celgene was terminated following the BMS acquisition, and amid intense market and pricing competition in the immuno-oncology sector in China.
You may also be interested in...
Deal Watch: Sanofi Teams Up With Biond On Novel Checkpoint Inhibitor
Days after buying Kymab, Sanofi partners with Israel’s Biond on IO candidate targeting ILT2. Gilead again tackles functional cure of hepatitis B in alliance with Vir.
The (Non-COVID) Clinical Trial Hits And Misses Of 2020
Putting aside the coronavirus pandemic for a while, and turning to industry’s more bread and butter R&D activities, Scrip takes a look at the industry’s biggest clinical trial hits and misses of the year.
Novartis Hits Spartalizumab Phase III Setback In Melanoma
Novartis’s attempts to enter the PD1 market by combining its investigational immunotherapy spartalizumab with its Tafinlar and Mekinist BRAF/MEK combination have come unstuck, leaving Roche to the field.
Need a specific report? 1000+ reports available
Buy Reports